Author

Amro M. Abdelrahman

Mayo ClinicORCID 0000-0001-9865-0551Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Assay:ChIP-seq· 2 Research Focus:chromatin & epigenetic regulation· 2 Research Focus:drug response / drug discovery· 2 Research Focus:gene regulatory network inference· 2

Frequent Co-Authors

Mark Joseph TrutyiD· 4 shared Akhilesh PandeyiD· 2 shared Danielle Marie CarlsoniD· 2 shared Dong‐Gi MuniD· 2 shared Enis H. OzmertiD· 2 shared Erik JesseniD· 2 shared Gregory James GoresiD· 2 shared Hendrien KuipersiD· 2 shared

Activity by Year

2026-2026 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

Mark Joseph TrutyORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

ESCRT-dependent YAP degradation by AKT blockade overcomes adaptive resistance to RAS(ON) inhibition in pancreatobiliary cancer

Jack W. Sample, Enis Özmert, Brandon A. Wilbanks, Danielle Marie Carlson, Hidemi Nishi, Amro M. Abdelrahman, Erik Jessen, Meina Cai, Dong‐Gi Mun, Hendrien Kuipers, Anna Splinter, Alexander L. Ticho, Nathan W. Werneburg, Akhilesh Pandey, Mark Joseph Truty, , Rory L. Smoot

This study identifies AKT as a regulator of YAP stability and shows that AKT inhibition triggers ESCRT-dependent YAP degradation, enhancing the efficacy of RAS inhibition in pancreatobiliary cancers.

bioRxiv · Oct 20, 2026 · PreprintCancer Biology

KLF5 controls subtype-independent highly interactive enhancers in pancreatic cancer to regulate cell survival

Thomas L. Ekstrom, Zhangshuai Dai, Julia Thiel, Akshay Kanakan, Bishakha Joyeeta Saha, Meghana Manjunath, Nadine Schacherer, Pavlos Bousounis, Emily L. Siegler, Amro M. Abdelrahman, Yara Souto, Frank Eßmann, Zeynab Najafova, Sven Beyes, Mark Joseph Truty, , Steven A. Johnsen

This study identifies KLF5-bound enhancers in pancreatic cancer that regulate cell survival, showing their subtype-independent role in maintaining tumor viability.

Science Advances · Mar 18, 2026Peer-reviewedCancer Biology

Epigenetic Context Defines the Transcriptional Activity of Canonical and Noncanonical NF-κB Signaling in Pancreatic Cancer

Joana E. Aggrey-Fynn, Joshua Busch, Dominik Saul, Ashish Rajput, Kerstin Willecke, Meghana Manjunath, Nicole Klimt, Kothai Rajendran, Nadine Schacherer, Wanwan Ge, Julia Thiel, Amro Abdelrahman, Mark Joseph Truty, Meng Dong, Steven A. Johnsen

This study identifies TNF and TWEAK as activators of canonical and noncanonical NF-κB signaling in PDAC, revealing distinct epigenetic dependencies of RELA and RELB.

Cell Death Discovery · Mar 17, 2026Peer-reviewedCancer Biology

Multiomics-driven discovery of predictive biomarkers and strategies to overcome resistance to SFK-YAP inhibition in cholangiocarcinoma

Hendrien Kuipers, Danielle Marie Carlson, Erik Jessen, Aushinie M. Abeynayake, Jack W. Sample, Dong‐Gi Mun, Jennifer L. Tomlinson, Amro M. Abdelrahman, Nathan W. Werneburg, Binbin Li, Enis H. Ozmert, Caitlin B. Conboy, Mitesh J. Borad, Mark Joseph Truty, Akhilesh Pandey, , Rory L. Smoot

This study identifies biomarkers and resistance mechanisms to SFK-YAP inhibition in cholangiocarcinoma using multiomic profiling and shows synergy with chemotherapy.

bioRxiv · Jan 23, 2026 · PreprintCancer Biology